Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38411622.
- Also identified by DOI 10.1093/cid/ciae105 and PMC identifier 11844219.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19-.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment.
Medical subject headings
- Ritonavir
- Hospitalization
- COVID-19
- SARS-CoV-2
- Antiviral Agents
- COVID-19 Vaccines